WHSC1L1 (D4N9N) Rabbit mAb #92056
- WB
- IP
- IHC
- F
Supporting Data
| REACTIVITY | H M R Mk |
| SENSITIVITY | Endogenous |
| MW (kDa) | 80-90, 180 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
- IHC-Immunohistochemistry
- F-Flow Cytometry
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
- Mk-Monkey
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:200 |
| Immunohistochemistry (Paraffin) | 1:200 |
| Flow Cytometry (Fixed/Permeabilized) | 1:400 |
Storage
For a carrier free (BSA and azide free) version of this product see product #33839.
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro117 of human WHSC1L1 protein.
Background
Wolf-Hirschhorn syndrome candidate 1-like protein 1 (WHSC1L1), also known as histone-lysine N-methyltransferase NSD3, is a SET domain-containing histone methyltransferase protein that methylates histone H3 on lysine 4 (H3K4me) and lysine 27 (H3K27me) (1). Methylation of histone H3 lysine 4 is associated with transcriptional activation, while methylation of histone H3 lysine 27 is associated with transcriptional repression. WHSC1L1 can function as an oncogene or a tumor suppressor protein, depending on cell context, and has been shown to regulate expression of a number of genes associated with cell cycle (2). Amplification and/or increased expression of WHSC1L1 in breast, lung, and liver cancer increases growth and survival, and is associated with poor prognosis (2-5). In addition, the NSD3 gene has been found fused with the nuclear pore complex protein NUP98 gene in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), and fused with the NUT gene in NUT midline carcinomas (6-10).
- Morishita, M. et al. (2014) BMC Struct Biol 14, 25.
- Zhou, Z. et al. (2010) Biochem Biophys Res Commun 398, 565-70.
- Angrand, P.O. et al. (2001) Genomics 74, 79-88.
- Yang, Z.Q. et al. (2010) Cancer Res 70, 8487-97.
- Kang, D. et al. (2013) Genes Chromosomes Cancer 52, 126-39.
- Rosati, R. et al. (2002) Blood 99, 3857-60.
- Taketani, T. et al. (2009) Cancer Genet Cytogenet 190, 108-12.
- French, C.A. et al. (2014) Cancer Discov 4, 928-41.
- Suzuki, S. et al. (2015) Pathol Res Pract 211, 404-8.
- Kuroda, S. et al. (2015) Case Rep Pathol 2015, 572951.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.